{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:06:51Z","timestamp":1785434811271,"version":"3.56.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["16FTF29630016"],"award-info":[{"award-number":["16FTF29630016"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["16SFRN31720000"],"award-info":[{"award-number":["16SFRN31720000"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health &amp; Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL135886"],"award-info":[{"award-number":["HL135886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["HL122987"],"award-info":[{"award-number":["HL122987"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiovascular disease constitutes the leading cause of mortality in patients with chronic kidney disease (CKD) and end-stage renal disease. Despite increasing recognition of a close interplay between kidney dysfunction and cardiovascular disease, termed cardiorenal syndrome (CRS), the underlying mechanisms of CRS remain poorly understood. Here we report the development of pathological cardiac hypertrophy and fibrosis in early stage non-uremic CKD. Moderate kidney failure was induced three weeks after unilateral urinary obstruction (UUO) in mice. We observed pathological cardiac hypertrophy and increased fibrosis in UUO-induced CKD (UUO\/CKD) animals. Further analysis indicated that this cardiac fibrosis was associated with increased expression of transforming growth factor \u03b2 (TGF-\u03b2) along with significant upregulation of Smad 2\/3 signaling in the heart. Moreover early treatment of UUO\/CKD animals with an angiotensin-converting-enzyme inhibitor (ACE I), Enalapril, significantly attenuated cardiac fibrosis. Enalapril antagonized activation of the TGF-\u03b2 signaling pathway in the UUO\/CKD heart. In summary our study demonstrates the presence of pathological cardiac hypertrophy and fibrosis in mice early in UUO-induced CKD, in association with early activation of the TGF-\u03b2\/Smad signaling pathway. We also demonstrate the beneficial effect of ACE I in alleviating this early fibrogenic process in the heart in UUO\/CKD animals.<\/jats:p>","DOI":"10.1038\/s41598-018-34216-x","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T09:18:39Z","timestamp":1540459119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pathological cardiac remodeling occurs early in CKD mice from unilateral urinary obstruction, and is attenuated by Enalapril"],"prefix":"10.1038","volume":"8","author":[{"given":"Onju","family":"Ham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua A. Jenny","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"34216_CR1","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1113\/jphysiol.2014.273078","volume":"592","author":"S Lekawanvijit","year":"2014","unstructured":"Lekawanvijit, S. & Krum, H. Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins. J Physiol 592, 3969\u20133983 (2014).","journal-title":"J Physiol"},{"key":"34216_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrneph.2013.250","volume":"10","author":"B Braam","year":"2014","unstructured":"Braam, B., Joles, J. A., Danishwar, A. H. & Gaillard, C. A. Cardiorenal syndrome\u2013current understanding and future perspectives. Nat Rev Nephrol 10, 48\u201355 (2014).","journal-title":"Nat Rev Nephrol"},{"key":"34216_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1440-1681.2011.05487.x","volume":"38","author":"P Boor","year":"2011","unstructured":"Boor, P. & Floege, J. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 38, 441\u2013450 (2011).","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"34216_CR4","first-page":"249","volume":"20","author":"GM London","year":"1991","unstructured":"London, G. M., Marchais, S. J., Guerin, A. P., Fabiani, F. & Metivier, F. Cardiovascular function in hemodialysis patients. Adv Nephrol Necker Hosp 20, 249\u2013273 (1991).","journal-title":"Adv Nephrol Necker Hosp"},{"key":"34216_CR5","first-page":"920195","volume":"2011","author":"BN Shah","year":"2010","unstructured":"Shah, B. N. & Greaves, K. The cardiorenal syndrome: a review. Int J Nephrol 2011, 920195 (2010).","journal-title":"Int J Nephrol"},{"key":"34216_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","volume":"31","author":"C Ronco","year":"2010","unstructured":"Ronco, C. et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31, 703\u2013711 (2010).","journal-title":"Eur Heart J"},{"key":"34216_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(16)00033-4","volume":"4","author":"R Vanholder","year":"2016","unstructured":"Vanholder, R. et al. Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol 4, 360\u2013373 (2016).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"34216_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1525-139X.2003.16023.x","volume":"16","author":"GM London","year":"2003","unstructured":"London, G. M. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 16, 85\u201394 (2003).","journal-title":"Semin Dial"},{"key":"34216_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0889-8529(18)30391-8","volume":"18","author":"R Arem","year":"1989","unstructured":"Arem, R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 18, 103\u2013121 (1989).","journal-title":"Endocrinol Metab Clin North Am"},{"key":"34216_CR10","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2215\/CJN.00950208","volume":"3","author":"S Kato","year":"2008","unstructured":"Kato, S. et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3, 1526\u20131533 (2008).","journal-title":"Clin J Am Soc Nephrol"},{"key":"34216_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.jrn.2011.10.020","volume":"22","author":"ND Vaziri","year":"2012","unstructured":"Vaziri, N. D., Pahl, M. V., Crum, A. & Norris, K. Effect of uremia on structure and function of immune system. J Ren Nutr 22, 149\u2013156 (2012).","journal-title":"J Ren Nutr"},{"key":"34216_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep34790","volume":"6","author":"Y Ryu","year":"2016","unstructured":"Ryu, Y. et al. Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity. Sci Rep 6, 34790 (2016).","journal-title":"Sci Rep"},{"key":"34216_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E. & Blaxall, B. C. Cardiac Fibrosis: The Fibroblast Awakens. Circ Res 118, 1021\u20131040 (2016).","journal-title":"Circ Res"},{"key":"34216_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1755-1536-5-15","volume":"5","author":"D Fan","year":"2012","unstructured":"Fan, D., Takawale, A., Lee, J. & Kassiri, Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5, 15 (2012).","journal-title":"Fibrogenesis Tissue Repair"},{"key":"34216_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cvr\/cvq308","volume":"89","author":"EE Creemers","year":"2011","unstructured":"Creemers, E. E. & Pinto, Y. M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 89, 265\u2013272 (2011).","journal-title":"Cardiovasc Res"},{"key":"34216_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/CIRCULATIONAHA.109.850677","volume":"121","author":"RR Chaturvedi","year":"2010","unstructured":"Chaturvedi, R. R. et al. Passive stiffness of myocardium from congenital heart disease and implications for diastole. Circulation 121, 979\u2013988 (2010).","journal-title":"Circulation"},{"key":"34216_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1139\/Y09-105","volume":"87","author":"L Espira","year":"2009","unstructured":"Espira, L. & Czubryt, M. P. Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol 87, 996\u20131008 (2009).","journal-title":"Can J Physiol Pharmacol"},{"key":"34216_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ndt\/5.1.39","volume":"5","author":"G Mall","year":"1990","unstructured":"Mall, G., Huther, W., Schneider, J., Lundin, P. & Ritz, E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5, 39\u201344 (1990).","journal-title":"Nephrol Dial Transplant"},{"key":"34216_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol 12, 325\u2013338 (2016).","journal-title":"Nat Rev Nephrol"},{"key":"34216_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","volume":"29","author":"A Biernacka","year":"2011","unstructured":"Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-beta signaling in fibrosis. Growth Factors 29, 196\u2013202 (2011).","journal-title":"Growth Factors"},{"key":"34216_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2567.2006.02336.x","volume":"118","author":"R Khan","year":"2006","unstructured":"Khan, R. & Sheppard, R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118, 10\u201324 (2006).","journal-title":"Immunology"},{"key":"34216_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","volume":"35","author":"JN Cohn","year":"2000","unstructured":"Cohn, J. N., Ferrari, R. & Sharpe, N. Cardiac remodeling\u2013concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35, 569\u2013582 (2000).","journal-title":"J Am Coll Cardiol"},{"key":"34216_CR23","doi-asserted-by":"publisher","first-page":"e74535","DOI":"10.1371\/journal.pone.0074535","volume":"8","author":"F Zhu","year":"2013","unstructured":"Zhu, F. et al. Senescent cardiac fibroblast is critical for cardiac fibrosis after myocardial infarction. PLoS One 8, e74535 (2013).","journal-title":"PLoS One"},{"key":"34216_CR24","first-page":"158","volume":"2","author":"A Biernacka","year":"2011","unstructured":"Biernacka, A. & Frangogiannis, N. G. Aging and Cardiac Fibrosis. Aging Dis 2, 158\u2013173 (2011).","journal-title":"Aging Dis"},{"key":"34216_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.recesp.2010.10.015","volume":"64","author":"SS Rhee","year":"2011","unstructured":"Rhee, S. S. & Pearce, E. N. Update: Systemic Diseases and the Cardiovascular System (II). The endocrine system and the heart: a review. Rev Esp Cardiol 64, 220\u2013231 (2011).","journal-title":"Rev Esp Cardiol"},{"key":"34216_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0008-6363(98)00305-8","volume":"41","author":"A Nicoletti","year":"1999","unstructured":"Nicoletti, A. & Michel, J. B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 41, 532\u2013543 (1999).","journal-title":"Cardiovasc Res"},{"key":"34216_CR27","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1161\/CIRCULATIONAHA.112.115592","volume":"126","author":"S Das","year":"2012","unstructured":"Das, S. et al. Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation 126, 2208\u20132219 (2012).","journal-title":"Circulation"},{"key":"34216_CR28","doi-asserted-by":"publisher","first-page":"F1253","DOI":"10.1152\/ajprenal.00392.2012","volume":"303","author":"LG Bongartz","year":"2012","unstructured":"Bongartz, L. G. et al. Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol 303, F1253\u20131263 (2012).","journal-title":"Am J Physiol Renal Physiol"},{"key":"34216_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2015.00465","volume":"6","author":"TD Hewitson","year":"2015","unstructured":"Hewitson, T. D., Holt, S. G. & Smith, E. R. Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human Pathology. Front Immunol 6, 465 (2015).","journal-title":"Front Immunol"},{"key":"34216_CR30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/jcmm.12813","volume":"20","author":"J Yin","year":"2016","unstructured":"Yin, J. et al. Renalase attenuates hypertension, renal injury and cardiac remodelling in rats with subtotal nephrectomy. J Cell Mol Med 20, 1106\u20131117 (2016).","journal-title":"J Cell Mol Med"},{"key":"34216_CR31","first-page":"20","volume":"4","author":"M Malek","year":"2015","unstructured":"Malek, M. & Nematbakhsh, M. Renal ischemia\/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 4, 20\u201327 (2015).","journal-title":"J Renal Inj Prev"},{"key":"34216_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ihj.2017.01.005","volume":"69","author":"L Di Lullo","year":"2017","unstructured":"Di Lullo, L. et al. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Indian Heart J 69, 255\u2013265 (2017).","journal-title":"Indian Heart J"},{"key":"34216_CR33","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1097\/01.ASN.0000064946.94590.46","volume":"14","author":"KJ Kelly","year":"2003","unstructured":"Kelly, K. J. Distant effects of experimental renal ischemia\/reperfusion injury. J Am Soc Nephrol 14, 1549\u20131558 (2003).","journal-title":"J Am Soc Nephrol"},{"key":"34216_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-59745-352-3_4","volume":"466","author":"TD Hewitson","year":"2009","unstructured":"Hewitson, T. D., Ono, T. & Becker, G. J. Small animal models of kidney disease: a review. Methods Mol Biol 466, 41\u201357 (2009).","journal-title":"Methods Mol Biol"},{"key":"34216_CR35","doi-asserted-by":"crossref","unstructured":"Chinnappa, S. et al. Early and asymptomatic cardiac dysfunction in chronic kidney disease. Nephrol Dial Transplant (2017).","DOI":"10.1093\/ndt\/gfx064"},{"key":"34216_CR36","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/ndt\/gft071","volume":"28","author":"GJ Becker","year":"2013","unstructured":"Becker, G. J. & Hewitson, T. D. Animal models of chronic kidney disease: useful but not perfect. Nephrol Dial Transplant 28, 2432\u20132438 (2013).","journal-title":"Nephrol Dial Transplant"},{"key":"34216_CR37","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.bbadis.2013.07.023","volume":"1832","author":"E Dirkx","year":"2013","unstructured":"Dirkx, E., da Costa Martins, P. A. & De Windt, L. J. Regulation of fetal gene expression in heart failure. Biochim Biophys Acta 1832, 2414\u20132424 (2013).","journal-title":"Biochim Biophys Acta"},{"key":"34216_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.hfc.2005.03.006","volume":"1","author":"G Selvetella","year":"2005","unstructured":"Selvetella, G. & Lembo, G. Mechanisms of cardiac hypertrophy. Heart Fail Clin 1, 263\u2013273 (2005).","journal-title":"Heart Fail Clin"},{"key":"34216_CR39","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev.physiol.59.1.551","volume":"59","author":"J Sadoshima","year":"1997","unstructured":"Sadoshima, J. & Izumo, S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59, 551\u2013571 (1997).","journal-title":"Annu Rev Physiol"},{"key":"34216_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000063551","volume":"20","author":"K Tyralla","year":"2002","unstructured":"Tyralla, K. & Amann, K. Cardiovascular changes in renal failure. Blood Purif 20, 462\u2013465 (2002).","journal-title":"Blood Purif"},{"key":"34216_CR41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","volume":"51","author":"M Dobaczewski","year":"2011","unstructured":"Dobaczewski, M., Chen, W. & Frangogiannis, N. G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 51, 600\u2013606 (2011).","journal-title":"J Mol Cell Cardiol"},{"key":"34216_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cardiores.2006.10.002","volume":"74","author":"M Bujak","year":"2007","unstructured":"Bujak, M. & Frangogiannis, N. G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74, 184\u2013195 (2007).","journal-title":"Cardiovasc Res"},{"key":"34216_CR43","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1161\/01.RES.0000221824.87718.c0","volume":"98","author":"D Sorescu","year":"2006","unstructured":"Sorescu, D. Smad3 mediates angiotensin II- and TGF-beta1-induced vascular fibrosis: Smad3 thickens the plot. Circ Res 98, 988\u2013989 (2006).","journal-title":"Circ Res"},{"key":"34216_CR44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0735-1097(03)00845-3","volume":"42","author":"EL Schiffrin","year":"2003","unstructured":"Schiffrin, E. L. & Touyz, R. M. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 42, 911\u2013913 (2003).","journal-title":"J Am Coll Cardiol"},{"key":"34216_CR45","doi-asserted-by":"publisher","first-page":"495349","DOI":"10.4061\/2011\/495349","volume":"2011","author":"RE Katholi","year":"2011","unstructured":"Katholi, R. E. & Couri, D. M. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011, 495349 (2011).","journal-title":"Int J Hypertens"},{"key":"34216_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/BF00944788","volume":"147","author":"W Linz","year":"1995","unstructured":"Linz, W. et al. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol Cell Biochem 147, 89\u201397 (1995).","journal-title":"Mol Cell Biochem"},{"key":"34216_CR47","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1161\/01.CIR.90.3.1410","volume":"90","author":"EO Weinberg","year":"1994","unstructured":"Weinberg, E. O. et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90, 1410\u20131422 (1994).","journal-title":"Circulation"},{"key":"34216_CR48","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1172\/JCI69666","volume":"124","author":"EM Gallo","year":"2014","unstructured":"Gallo, E. M. et al. Angiotensin II-dependent TGF-beta signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest 124, 448\u2013460 (2014).","journal-title":"J Clin Invest"},{"key":"34216_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nm1536","volume":"13","author":"RD Cohn","year":"2007","unstructured":"Cohn, R. D. et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13, 204\u2013210 (2007).","journal-title":"Nat Med"},{"key":"34216_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0895-7061(99)00152-1","volume":"13","author":"N Fukuda","year":"2000","unstructured":"Fukuda, N. et al. Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells. Am J Hypertens 13, 191\u2013198 (2000).","journal-title":"Am J Hypertens"},{"key":"34216_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000057367","volume":"24","author":"G Wolf","year":"1998","unstructured":"Wolf, G. Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 24, 174\u2013180 (1998).","journal-title":"Miner Electrolyte Metab"},{"key":"34216_CR52","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fimmu.2015.00340","volume":"6","author":"PR Gajjala","year":"2015","unstructured":"Gajjala, P. R., Sanati, M. & Jankowski, J. Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities. Front Immunol 6, 340 (2015).","journal-title":"Front Immunol"},{"key":"34216_CR53","first-page":"2918","volume":"18","author":"M Liu","year":"2014","unstructured":"Liu, M. et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 18, 2918\u20132926 (2014).","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"34216_CR54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jfma.2015.06.009","volume":"114","author":"YW Liu","year":"2015","unstructured":"Liu, Y. W. et al. The role of echocardiographic study in patients with chronic kidney disease. J Formos Med Assoc 114, 797\u2013805 (2015).","journal-title":"J Formos Med Assoc"},{"key":"34216_CR55","doi-asserted-by":"publisher","first-page":"937398","DOI":"10.1155\/2014\/937398","volume":"2014","author":"L Segall","year":"2014","unstructured":"Segall, L., Nistor, I. & Covic, A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int 2014, 937398 (2014).","journal-title":"Biomed Res Int"},{"key":"34216_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2174\/1573403X10666140214122234","volume":"9","author":"Q Cai","year":"2013","unstructured":"Cai, Q., Mukku, V. K. & Ahmad, M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev 9, 331\u2013339 (2013).","journal-title":"Curr Cardiol Rev"},{"key":"34216_CR57","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1681\/ASN.2011111115","volume":"23","author":"MM Mitsnefes","year":"2012","unstructured":"Mitsnefes, M. M. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23, 578\u2013585 (2012).","journal-title":"J Am Soc Nephrol"},{"key":"34216_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.14814\/phy2.12732","volume":"4","author":"PD Winterberg","year":"2016","unstructured":"Winterberg, P. D. et al. Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD). Physiological reports 4, 5 (2016).","journal-title":"Physiological reports"},{"key":"34216_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000447542","volume":"7","author":"J Zhang","year":"2016","unstructured":"Zhang, J., Fallahzadeh, M. K. & McCullough, P. A. Aging Male Spontaneously Hypertensive Rat as an Animal Model for the Evaluation of the Interplay between Contrast-Induced Acute Kidney Injury and Cardiorenal Syndrome in Humans. Cardiorenal Med 7, 1\u201310 (2016).","journal-title":"Cardiorenal Med"},{"key":"34216_CR60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10741-010-9197-z","volume":"16","author":"S Taddei","year":"2011","unstructured":"Taddei, S., Nami, R., Bruno, R. M., Quatrini, I. & Nuti, R. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail Rev 16, 615\u2013620 (2011).","journal-title":"Heart Fail Rev"},{"key":"34216_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1046\/j.1525-139X.2003.16025.x","volume":"16","author":"A Levin","year":"2003","unstructured":"Levin, A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 16, 101\u2013105 (2003).","journal-title":"Semin Dial"},{"key":"34216_CR62","doi-asserted-by":"crossref","unstructured":"Dikow, R., Adamczak, M., Henriquez, D. E. & Ritz, E. Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl. 5\u201310 (2002).","DOI":"10.1046\/j.1523-1755.61.s80.3.x"},{"key":"34216_CR63","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ki.2011.223","volume":"80","author":"CA Herzog","year":"2011","unstructured":"Herzog, C. A. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80, 572\u2013586 (2011).","journal-title":"Kidney Int"},{"key":"34216_CR64","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/ki.1988.71","volume":"33","author":"G Mall","year":"1988","unstructured":"Mall, G. et al. Myocardial interstitial fibrosis in experimental uremia\u2013implications for cardiac compliance. Kidney Int 33, 804\u2013811 (1988).","journal-title":"Kidney Int"},{"key":"34216_CR65","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1681\/ASN.2008040402","volume":"20","author":"MP Schlaich","year":"2009","unstructured":"Schlaich, M. P. et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 20, 933\u2013939 (2009).","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"34216_CR66","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/ijms17070797","volume":"17","author":"Natalia Mu\u00f1oz-Durango","year":"2016","unstructured":"Munoz-Durango, N. et al. Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension. Int J Mol Sci 17 (2016).","journal-title":"International Journal of Molecular Sciences"},{"key":"34216_CR67","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20150469","volume":"130","author":"M Volpe","year":"2016","unstructured":"Volpe, M., Carnovali, M. & Mastromarino, V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 130, 57\u201377 (2016).","journal-title":"Clin Sci (Lond)"},{"key":"34216_CR68","doi-asserted-by":"publisher","first-page":"R104","DOI":"10.1152\/ajpregu.00209.2013","volume":"305","author":"T Cao","year":"2013","unstructured":"Cao, T. & Feng, Y. The (pro)renin receptor and body fluid homeostasis. Am J Physiol Regul Integr Comp Physiol 305, R104\u2013106 (2013).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"34216_CR69","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000368549","volume":"41","author":"N Sun","year":"2016","unstructured":"Sun, N. et al. Angiotensin-Converting Enzyme Inhibitor (ACEI)-Mediated Amelioration in Renal Fibrosis Involves Suppression of Mast Cell Degranulation. Kidney & blood pressure research 41, 108\u2013118 (2016).","journal-title":"Kidney & blood pressure research"},{"key":"34216_CR70","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/ki.2008.690","volume":"75","author":"AM Siedlecki","year":"2009","unstructured":"Siedlecki, A. M., Jin, X. & Muslin, A. J. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75, 800\u2013808 (2009).","journal-title":"Kidney Int"},{"key":"34216_CR71","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1055\/s-0037-1613580","volume":"89","author":"JP Schanstra","year":"2003","unstructured":"Schanstra, J. P. et al. The protective effect of angiotensin converting enzyme inhibition in experimental renal fibrosis in mice is not mediated by bradykinin B2 receptor activation. Thrombosis and haemostasis 89, 735\u2013740 (2003).","journal-title":"Thrombosis and haemostasis"},{"key":"34216_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0272-6386(95)90167-1","volume":"26","author":"S Klahr","year":"1995","unstructured":"Klahr, S., Ishidoya, S. & Morrissey, J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 26, 141\u2013146 (1995).","journal-title":"Am J Kidney Dis"},{"key":"34216_CR73","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/ki.1995.183","volume":"47","author":"S Ishidoya","year":"1995","unstructured":"Ishidoya, S., Morrissey, J., McCracken, R., Reyes, A. & Klahr, S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47, 1285\u20131294 (1995).","journal-title":"Kidney Int"},{"key":"34216_CR74","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/10641963.2016.1235184","volume":"39","author":"L Sedlakova","year":"2017","unstructured":"Sedlakova, L. et al. Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5\/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Hypertens 39, 183\u2013195 (2017).","journal-title":"Clin Exp Hypertens"},{"key":"34216_CR75","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/ki.2012.170","volume":"82","author":"JM Luther","year":"2012","unstructured":"Luther, J. M. et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int 82, 643\u2013651 (2012).","journal-title":"Kidney Int"},{"key":"34216_CR76","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma, T. K., Kam, K. K., Yan, B. P. & Lam, Y. Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160, 1273\u20131292 (2010).","journal-title":"Br J Pharmacol"},{"key":"34216_CR77","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000313363","volume":"31","author":"HM Siragy","year":"2010","unstructured":"Siragy, H. M. & Carey, R. M. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 31, 541\u2013550 (2010).","journal-title":"Am J Nephrol"},{"key":"34216_CR78","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1291\/hypres.31.175","volume":"31","author":"M Nangaku","year":"2008","unstructured":"Nangaku, M. & Fujita, T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 31, 175\u2013184 (2008).","journal-title":"Hypertens Res"},{"key":"34216_CR79","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.ajkd.2014.12.016","volume":"66","author":"DM Charytan","year":"2015","unstructured":"Charytan, D. M., Fishbane, S., Malyszko, J., McCullough, P. A. & Goldsmith, D. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis 66, 196\u2013205 (2015).","journal-title":"Am J Kidney Dis"},{"key":"34216_CR80","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000349966","volume":"182","author":"PA McCullough","year":"2013","unstructured":"McCullough, P. A. et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 182, 82\u201398 (2013).","journal-title":"Contrib Nephrol"},{"key":"34216_CR81","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/0975-3583.95379","volume":"3","author":"SC Aundhakar","year":"2012","unstructured":"Aundhakar, S. C., Mahajan, S. K., Mane, M. B., Lakhotia, A. N. & Mahajani, V. V. Cardiorenal syndrome: Resistant to diuretics, sensitive to ultraflitration. J Cardiovasc Dis Res 3, 173\u2013175 (2012).","journal-title":"J Cardiovasc Dis Res"},{"key":"34216_CR82","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/hr.2013.134","volume":"37","author":"R Yoshitomi","year":"2014","unstructured":"Yoshitomi, R. et al. Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease. Hypertens Res 37, 246\u2013252 (2014).","journal-title":"Hypertens Res"},{"key":"34216_CR83","doi-asserted-by":"publisher","first-page":"e41281","DOI":"10.1371\/journal.pone.0041281","volume":"7","author":"S Lekawanvijit","year":"2012","unstructured":"Lekawanvijit, S. et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 7, e41281 (2012).","journal-title":"PLoS One"},{"key":"34216_CR84","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/eurheartj\/ehp574","volume":"31","author":"S Lekawanvijit","year":"2010","unstructured":"Lekawanvijit, S. et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 31, 1771\u20131779 (2010).","journal-title":"Eur Heart J"},{"issue":"Suppl B","key":"34216_CR85","doi-asserted-by":"publisher","first-page":"25B","DOI":"10.1016\/S0828-282X(08)71027-4","volume":"24","author":"PP Liu","year":"2008","unstructured":"Liu, P. P. Cardiorenal syndrome in heart failure: a cardiologist\u2019s perspective. Can J Cardiol 24(Suppl B), 25B\u201329B (2008).","journal-title":"Can J Cardiol"},{"key":"34216_CR86","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.bjp.0707353","volume":"152","author":"XJ Du","year":"2007","unstructured":"Du, X. J. Divergence of hypertrophic growth and fetal gene profile: the influence of beta-blockers. Br J Pharmacol 152, 169\u2013171 (2007).","journal-title":"Br J Pharmacol"},{"key":"34216_CR87","doi-asserted-by":"publisher","first-page":"H8","DOI":"10.1152\/ajpheart.01303.2004","volume":"289","author":"K Berenji","year":"2005","unstructured":"Berenji, K., Drazner, M. H., Rothermel, B. A. & Hill, J. A. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289, H8\u2013H16 (2005).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"34216_CR88","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardiores.2004.04.030","volume":"63","author":"S Rosenkranz","year":"2004","unstructured":"Rosenkranz, S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63, 423\u2013432 (2004).","journal-title":"Cardiovasc Res"},{"key":"34216_CR89","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.acvd.2013.01.004","volume":"106","author":"Z Yang","year":"2013","unstructured":"Yang, Z. et al. Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats. Arch Cardiovasc Dis 106, 196\u2013201 (2013).","journal-title":"Arch Cardiovasc Dis"},{"key":"34216_CR90","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5507\/bp.2011.026","volume":"155","author":"AR Fallahzadeh","year":"2011","unstructured":"Fallahzadeh, A. R., Khazaei, M. & Sharifi, M. R. Restoration of angiogenesis by enalapril in diabetic hindlimb ischemic rats. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155, 137\u2013142 (2011).","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"34216_CR91","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.4049\/jimmunol.177.10.7233","volume":"177","author":"PG Arndt","year":"2006","unstructured":"Arndt, P. G. et al. Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. Journal of immunology (Baltimore. Md. 1950) 177, 7233\u20137241 (2006).","journal-title":"Journal of immunology (Baltimore. Md. 1950)"},{"key":"34216_CR92","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1242\/jcs.204842","volume":"130","author":"W Li","year":"2017","unstructured":"Li, W. et al. Ezrin directly interacts with AQP2 and promotes its endocytosis. J Cell Sci 130, 2914\u20132925 (2017).","journal-title":"J Cell Sci"},{"key":"34216_CR93","first-page":"02017","volume":"00038","author":"FA Mamuya","year":"2017","unstructured":"Mamuya, F. A. et al. Deletion of beta-1 integrin in collecting duct principal cells leads to tubular injury and renal medullary fibrosis. Am J Physiol Renal Physiol, ajprenal 00038, 02017 (2017).","journal-title":"Am J Physiol Renal Physiol, ajprenal"},{"key":"34216_CR94","doi-asserted-by":"publisher","first-page":"e32843","DOI":"10.1371\/journal.pone.0032843","volume":"7","author":"WL Rice","year":"2012","unstructured":"Rice, W. L. et al. Differential, phosphorylation dependent trafficking of AQP2 in LLC-PK1 cells. PLoS One 7, e32843 (2012).","journal-title":"PLoS One"},{"key":"34216_CR95","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1095\/biolreprod.108.075648","volume":"81","author":"PS Tanwar","year":"2009","unstructured":"Tanwar, P. S. et al. Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod 81, 545\u2013552 (2009).","journal-title":"Biol Reprod"},{"key":"34216_CR96","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13287-015-0012-6","volume":"6","author":"HY Choi","year":"2015","unstructured":"Choi, H. Y. et al. Mesenchymal stem cell-derived microparticles ameliorate peritubular capillary rarefaction via inhibition of endothelial-mesenchymal transition and decrease tubulointerstitial fibrosis in unilateral ureteral obstruction. Stem cell research & therapy 6, 18 (2015).","journal-title":"Stem cell research & therapy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34216-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:01:16Z","timestamp":1671620476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34216-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["34216"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-34216-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16087"}}